Last edition
News about "Stargardt disease"
Ascidian Therapeutics Completes STELLAR Trial Dose Escalation for ACDN-01 in Stargardt Disease
Ascidian Therapeutics completes Phase 1/2 STELLAR dose escalation for ACDN-01 in Stargardt disease, advances pediatric enrollment, and launches STARPATH prescreening to accelerate clinical trial access.
Stargardt Disease | 05/05/2026 | By News Bureau
AGC Biologics has partnered with AAVantgarde Bio to manufacture its dual-vector AAV gene therapies targeting inherited retinal disorders. Leveraging the BravoAAV platform, the collaboration aims to advance complex treatments designed to restore vision in patients with genetic blindness.
Stargardt Disease | 24/11/2025 | By Dineshwori | 162
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy